Endonovo Therapeutics Inc (OTCMKTS:ENDV) has got everyone’s attention as it maintains its place among the volume leaders on the bb’s. The stock is highly volatile trading between $0.1 and $0.8 in recent months.
The initial move up on ENDV came after the Company announced they are developing a next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics(TM) expanded and ex vivo enhanced stem cells from the human umbilical cord.
Endonovo Therapeutics Inc (OTCMKTS:ENDV) is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo’s Immunotronics(TM) platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration.
Endonovo’s Cytotronics(TM) platform provides for a method of expanding and enhancing the biological and therapeutic properties of cells for the development of next-generation cell therapies. The Company’s initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics(TM) platform and the treatment of Graft-Versus-Host Disease using its ex vivo expanded and enhanced stem cells.
Earlier this year ENDV announced the development of a large-scale method for the expansion of umbilical cord blood. ENDV says their technology could allow for a 10x increase in adult stem cell transplants and potentially increase the safety of these treatments by allowing for the expansion of sub-optimal cord blood products that are better matched to patients.
Endonovo’s technology consists of the co-culturing of cord blood mononuclear cells with a portion of the umbilical cord in a three-dimensional rotating wall vessel (RWV) bioreactor, allowing for the expansion of hematopoietic stem cells. The expanded cord blood products would meet the minimal cell requirements for the use of cord blood in adults and potentially result in enhanced engraftment and less toxicities, such as graft versus host disease (GVHD) that occur in lower level HLA matched cord blood units.
To Find out the inside Scoop on ENDV Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
In October ENDV announced two bioelectronic-based platforms for regenerative medicine: Immunotronics(TM), a non-invasive and non-implantable immuno-regulatory device designed to treat inflammatory conditions in vital organs, including acute organ failure; and Cytotronics(TM), a proprietary bioelectronic-based method of expanding and manipulating cells for the creation of cell therapies and tissue engineering.
Endonovo is concentrating its efforts on inflammatory conditions in vital organs and previously announced it’s in the pre-clinical phase of assessing its proprietary Immunotronic technology in the treatment of chronic and acute inflammatory conditions in the liver, including fulminant liver failure.
In November ENDV announced it is developing a next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics(TM) expanded and ex vivo enhanced stem cells from the human umbilical cord. Endonovo Chief Scientist, Dr. Donnie Rudd said “We have taken our method of expanding a population of immune privileged stem cells from the human umbilical cord and combined it with our Cytotronics platform to create large quantities of optimized immuno-regulatory stem cells that can be used as an allogeneic, off-the-shelf therapy for the treatment of Graft-Versus-Host Disease. Our Cytotronics platform is particularly suited to address many of the issues that have plagued stem cell therapies that have recently failed, such as their loss of potency and self-renewal when expanded ex vivo, their poor engraftment and their limited ability to survive when transplanted,” says Dr. Rudd.
Recently the Company announced it is commencing a pre-clinical study at a contract research organization to assess the therapeutic potential of its Immunotronics™ platform in the prevention of heart failure following myocardial infarction (MI). The pre-clinical study will evaluate the effect of the Company’s non-invasive electroceutical technology on cardiac function, post-MI remodeling, and infarct size, as well as angiogenesis (the development of new blood vessels). The study, estimated to be complete at the end of the first quarter of 2017, represents the first of several planned studies designed to evaluate the Company’s proprietary non-invasive electroceuticals in the treatment of vascular diseases and ischemia/reperfusion injury.
“We are leveraging the experience and proprietary knowledge of our scientific team, which has undertaken over 25 years of research and development in the field of bioelectromagnetic therapeutics in angiogenesis, neuroinflammation and ischemia to develop non-invasive treatments for substantially unmet clinical needs,” commented Endonovo Chairman and CEO, Alan Collier.
Currently trading at a $7.14 million market valuation ENDV has minimal assets or revenues and fast rising debt that could lead to dilution. But ENDV is an exciting story in small caps; the Company is developing bioelectronics-based products and therapies for regenerative medicine and just retained Holland & Knight to prepare and file the paperwork necessary to obtain an orphan drug designation. Stem cells have always been an explosive sector and ENDV is always one licensing, royalty deal or JV away from a parabolic move. The stock has shown us already is has runner in its blood. We will be updating on ENDV when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENDV.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in ENDV either long or short and we have not been compensated for this article.